DeutschNewstral
Article
Bbarrons.com on 2021-09-09 18:25
Biogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min read
Related news
Biogen shares soar as FDA reviewers support Alzheimer's drugSydney Morning Herald- WAlzheimer's drug from Biogen, partner receives FDA approvalwraltechwire.com
Biogen reanalyzes studies, presses ahead on Alzheimer's druglasvegassun.com- BBiogen Stock Is Falling Because Earnings Guidance Came Up Shortbarrons.com
- BMcDonald’s Is Jumping, Biogen Is Tumbling, and the Dow Is Soaringbarrons.com
Biogen data reignites debate over Alzheimer's cause as investors back off (Video)bizjournals.com- BBiogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug1 min readbarrons.com
- MBiogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decisionmarketwatch.com
Change at the top for Biogen after Alzheimer's drug flops - Tue, 03 May 2022 PSTapnews.com
Biogen cutting cost of Alzheimer's drugArkansas Online- MBiogen shares tumble on Alzheimer's candidate datamarketwatch.com
- BBiogen Is Spiking Because Its Alzheimer’s Drug Takes Another Step Toward Approvalbarrons.com
- BBiogen Stock Is Down on a Report That Few Have Received Its New Alzheimer's Therapy3 min readbarrons.com
Alzheimer's drug rollout off to slow startnwaonline.com
Biogen trial drug shows promise in fight against Alzheimer'sThe Japan Times- Biogen pays California biotech $350M upfront for Alzheimer's gene therapybizjournals.com
- Biogen analysts pounce on 'thin' Alzheimer's trial databizjournals.com
Biogen says new drug shows promise in combating Alzheimer'smetro.us